BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cady RJ, Shade CL, Cady RK. Advances in Drug Development for Acute Migraine: . Drugs 2012;72:2187-205. [DOI: 10.2165/11641120-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 van Hoogstraten WS, MaassenVanDenBrink A. The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse. J Headache Pain 2019;20:54. [PMID: 31096904 DOI: 10.1186/s10194-019-1007-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
2 Dodick DW. A Phase-by-Phase Review of Migraine Pathophysiology: Supplement Article. Headache: The Journal of Head and Face Pain 2018;58:4-16. [DOI: 10.1111/head.13300] [Cited by in Crossref: 175] [Cited by in F6Publishing: 187] [Article Influence: 35.0] [Reference Citation Analysis]
3 Al-salama ZT, Scott LJ. Sumatriptan Nasal Powder: A Review in Acute Treatment of Migraine. Drugs 2016;76:1477-84. [DOI: 10.1007/s40265-016-0641-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
4 Affaitati G, Martelletti P, Lopopolo M, Tana C, Massimini F, Cipollone F, Lapenna D, Giamberardino MA, Costantini R. Use of Nonsteroidal Anti-Inflammatory Drugs for Symptomatic Treatment of Episodic Headache. Pain Pract 2017;17:392-401. [PMID: 27207273 DOI: 10.1111/papr.12461] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
5 Sokolov AY, Lyubashina OA, Berkovich RR, Panteleev SS. Intravenous dextromethorphan/quinidine inhibits activity of dura-sensitive spinal trigeminal neurons in rats. Eur J Pain 2015;19:1086-94. [PMID: 25410439 DOI: 10.1002/ejp.631] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
6 Schriever J, Bühlen M, Broich K. [Current state of knowledge and developments in the prophylaxis and acute treatment of migraine]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2014;57:974-82. [PMID: 25028243 DOI: 10.1007/s00103-014-2000-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Silberstein SD, Stirpe JC. COX inhibitors for the treatment of migraine. Expert Opinion on Pharmacotherapy 2014;15:1863-74. [DOI: 10.1517/14656566.2014.937704] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
8 Yang LPH. Sumatriptan/Naproxen Sodium: A Review of Its Use in Adult Patients with Migraine. Drugs 2013;73:1339-55. [DOI: 10.1007/s40265-013-0099-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
9 Öztürk V. Acute Treatment of Migraine. Noro Psikiyatr Ars 2013;50:S26-9. [PMID: 28360580 DOI: 10.4274/Npa.y7299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]